Attovia Therapeutics, Inc.

ATTOReported to SECin USCIK 0002058707Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 160. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 160
Form 4 lines at Attovia Therapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
WALSH COLIN—Open-market buy$121,8885,744 sharesAug 28, 2026WALSH COLIN$121,888Buy · Aug 28Open-market buy5,744Aug 28, 2026
WALSH COLIN—Open-market buy$242,43511,398 sharesAug 28, 2026WALSH COLIN$242,435Buy · Aug 28Open-market buy11,398Aug 28, 2026
WALSH COLIN—Open-market buy$969,65745,588 sharesAug 28, 2026WALSH COLIN$969,657Buy · Aug 28Open-market buy45,588Aug 28, 2026
WALSH COLIN—Open-market buy$243,77511,488 sharesAug 28, 2026WALSH COLIN$243,775Buy · Aug 28Open-market buy11,488Aug 28, 2026
WALSH COLIN—Open-market buy$609,37528,717 sharesAug 28, 2026WALSH COLIN$609,375Buy · Aug 28Open-market buy28,717Aug 28, 2026